MedTrace Logo

A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer

NCT02667327 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2020-05-29

No results posted yet for this study

Summary

The purpose of this study is to determine whether Granexin gel is safe and effective in the treatment of diabetic foot ulcers.

Conditions

  • Diabetic Foot Ulcers

Interventions

DRUG

Granexin gel

Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.

OTHER

Vehicle gel

The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.

Sponsors & Collaborators

  • Xequel Bio, Inc.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-21
Primary Completion
2020-05-27
Completion
2020-05-27
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Hungary
  • India
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02667327 on ClinicalTrials.gov